Recent clinical trials of immunotherapy in non-small-cell lung cancer

Immunotherapy. 2019 Apr;11(6):461-466. doi: 10.2217/imt-2019-0021.

Authors

Stavros Gkolfinopoulos¹, Giannis Mountzios²

Affiliations

¹ Medical Oncology Department, BOC Oncology Center, Nicosia 2006, Cyprus.
² 2nd Medical Oncology Department, Henry Dunant Hospital Center, Athens 11526, Greece.

PMID: 30860438
DOI: 10.2217/imt-2019-0021

No abstract available

Keywords: atezolizumab; avelumab; checkpoint inhibitors; durvalumab; ipilimumab; nivolumab; non-small-cell lung cancer; pembrolizumab.

MeSH terms

Antineoplastic Agents, Immunological / therapeutic use*
Carcinoma, Non-Small-Cell Lung / immunology
Carcinoma, Non-Small-Cell Lung / therapy*
Clinical Trials as Topic
Costimulatory and Inhibitory T-Cell Receptors / antagonists & inhibitors
Humans
Immunotherapy / methods*
Lung Neoplasms / immunology
Lung Neoplasms / therapy*
Medical Oncology / trends*
Practice Guidelines as Topic
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
Costimulatory and Inhibitory T-Cell Receptors